Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cryoglobulinemia.

A Dispenzieri1, P D Gorevic

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Hematology/Oncology Clinics of North America
|January 8, 2000
PubMed
Summary
This summary is machine-generated.

Cryoglobulinemia involves immune complex disorders and B-cell neoplasms, causing vasculopathy. Future research needs to identify symptomatic factors and improve therapies for this complex condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024
Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023
Same author

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Blood cancer journal·2021
Same author

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.

Blood cancer journal·2021
Same author

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2021
Same author

Systemic amyloidosis from A (AA) to T (ATTR): a review.

Journal of internal medicine·2020
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Immunology
  • Hematology
  • Hepatology

Background:

  • Cryoglobulinemia presents across a range of conditions, from B-cell neoplasms to immune complex diseases.
  • Manifestations include ischemic vasculopathy, vasculitis, and glomerulonephritis, driven by antibody-antigen responses and immune complexes.
  • Hepatic dysfunction and lymphoproliferation are frequently associated with symptomatic cryoglobulinemia.

Purpose of the Study:

  • To delineate factors distinguishing symptomatic from asymptomatic cryoglobulinemia.
  • To elucidate pathogenic mechanisms of Hepatitis C Virus (HCV) in cryoglobulin formation.
  • To explore improved therapeutic strategies and systematic evaluation of existing treatments for cryoglobulinemia.

Main Methods:

  • Review of existing literature on cryoglobulinemia classification and pathogenesis.

Related Experiment Videos

  • Analysis of factors influencing cryoglobulin symptom presentation.
  • Evaluation of current and potential therapeutic interventions, including antiviral and immunomodulatory agents.

    • Main Results:

    • Cryoglobulinemia classification relies on Brouet's types (I, II, III), with future prognostication incorporating HCV status, viral factors, infections, and immune interactions.
    • Hepatitis C Virus (HCV) is a significant driver of cryoglobulin formation, though not universally present.
    • Current therapies like interferon (IFN) show limited efficacy and tolerability in HCV-associated cryoglobulinemia.

    Conclusions:

    • Further research is essential to understand the heterogeneity of cryoglobulinemia and identify triggers for symptomatic disease.
    • Developing novel and systematically studied therapeutic approaches is critical for effective management.
    • Personalized treatment strategies considering patient-specific factors like HCV, immune status, and B-cell clone burden are needed.